Published in J Dtsch Dermatol Ges on June 01, 2011
Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. J Invest Dermatol (2015) 0.89
Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. J Clin Aesthet Dermatol (2016) 0.83
It is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis. Patient Prefer Adherence (2012) 0.80
Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP). Arch Dermatol Res (2014) 0.80
Cost-of-illness in psoriasis: comparing inpatient and outpatient therapy. PLoS One (2013) 0.77
The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge. Postepy Dermatol Alergol (2014) 0.76
Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a systematic review and meta-analysis. Chin Med (2015) 0.75
[Psoriatic arthritis : Overview of drug therapy options and administration characteristics]. Z Rheumatol (2016) 0.75
[Differential diagnostic spectrum of psoriasis vs. psoriatic arthritis in skin and joints]. Z Rheumatol (2017) 0.75
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol (2006) 4.88
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med (2014) 3.36
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med (2012) 3.14
Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet (2010) 2.76
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet (2010) 2.66
[Dithranol in the treatment of scalp psoriasis]. J Dtsch Dermatol Ges (2003) 2.63
Report of a case of Schnitzler's syndrome treated successfully with interferon alpha 2b. Dermatology (2002) 2.37
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol (2011) 2.29
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 1.95
Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther (2008) 1.90
Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. J Invest Dermatol (2010) 1.89
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med (2002) 1.86
Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res (2006) 1.81
IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol (2007) 1.80
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) (2009) 1.76
More on PML in Patients Treated with Dimethyl Fumarate. N Engl J Med (2016) 1.73
Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res (2005) 1.65
Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol (2007) 1.64
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol (2007) 1.59
Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol (2008) 1.59
Nanoparticles--an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm (2006) 1.56
Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol (2006) 1.53
A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer (2009) 1.51
Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med (Berl) (2003) 1.51
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol (2005) 1.51
Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol (2003) 1.49
Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation. J Invest Dermatol (2013) 1.48
Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol (2012) 1.46
Developmental outcome in five children with Hurler syndrome after stem cell transplantation: a pilot study. Dev Med Child Neurol (2007) 1.46
Case reports of PML in patients treated for psoriasis. N Engl J Med (2013) 1.45
Immunopathogenesis of psoriasis. Exp Dermatol (2007) 1.44
Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci U S A (2009) 1.44
Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken) (2014) 1.43
Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol (2006) 1.41
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation (2010) 1.41
Regulation of the major isoform of human endothelin-converting enzyme-1 by a strong housekeeping promoter modulated by polymorphic microsatellites. J Hypertens (2003) 1.40
Virtual dermatohistopathology at http://www.pathowiki.org. J Dtsch Dermatol Ges (2012) 1.39
Clinical research in cutaneous T-cell lymphoma moving forward. Arch Dermatol (2008) 1.39
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother (2008) 1.35
Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg (2010) 1.33
Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol (2008) 1.32
40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol (2006) 1.31
Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum (2005) 1.31
Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res (2004) 1.30
Endothelin-1 potently induces Leão's cortical spreading depression in vivo in the rat: a model for an endothelial trigger of migrainous aura? Brain (2002) 1.30
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol (2010) 1.29
Porcine ear skin: an in vitro model for human skin. Skin Res Technol (2007) 1.28
Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol (2012) 1.28
Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol (2010) 1.27
Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. J Invest Dermatol (2009) 1.26
Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol (2008) 1.26
Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine--preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem (2006) 1.26
Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology (2014) 1.25
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges (2012) 1.25
Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer (2006) 1.21
Influence of fast lymphatic drainage on metastatic spread in cutaneous malignant melanoma: a prospective feasibility study. Eur J Nucl Med Mol Imaging (2003) 1.20
The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol (2009) 1.19
Adipokines and psoriasis. Exp Dermatol (2011) 1.17
PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol (2007) 1.15
Variations of hair follicle size and distribution in different body sites. J Invest Dermatol (2004) 1.15
Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol (2004) 1.14
Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res (2006) 1.12
Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J (2003) 1.12
Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol (2004) 1.11
Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J Invest Dermatol (2005) 1.10
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol (2007) 1.10
The role of hair follicles in the percutaneous absorption of caffeine. Br J Clin Pharmacol (2007) 1.10
Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol (2012) 1.09
IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med (2013) 1.09